Windtree Therapeutics Inc (WINT)

[ThurstonHowell]

Windtree’s Pipeline Attracts Two Chinese Firms in $80M Deal
Big Pharmaceutical Buyout Candidate,
Pennsylvania biotech Windtree Therapeutics has entered into a $78.9-million deal with Hong Kong-based Lee’s Pharmaceutical and its China affiliate, Zhaoke Pharmaceutical. At the core of the agreement are Windtree’s pulmonary pipeline treatments, particularly the KL4 surfactant and the drug-device combination AEROSURF, both for respiratory distress syndrome in preterm infants.

Lee and Zhaoke had previously won a regional license for KL4 and AEROSURF, paying an upfront $1 million for rights to Windtree’s pipeline products in the Greater China area. This week’s deal expands that coverage globally. In turn, the Asian companies will assume all funding responsibility over development, manufacturing, commercialization and intellectual property activities, while Windtree will remain entitled to commercial milestones and potential double-digit royalties.

After its execution, the agreement will conclude all of Windtree’s ongoing maintenance and operating costs for KL4.